Clinical Ink, an emerging entrepreneurial firm that has developed a clinical trials software platform that mimics the look and feel of a paper chart, is going back to investors to raise more cash.
Clinical Ink
According to an SEC filing, the Winston-Salem firm has closed on $1.7 million in new funding.
Nine investors have contributed to the round so far.
Clinical Ink hopes to raise $2.5 million.
The funding is a mix of debt and options.
Clinical Ink’s software platform SureSource (watch a video overview) is designed to capture clinical trial data during a subject visit on a tablet computer. While electronic data capture systems are widely used in clinical trials, replacing what was once a paper-intensive process, Clinical Ink says that it’s product makes the process of capturing clinical trial data more closely resemble the look and the usability of paper charts. Clinical Ink says its approach produces faster and cleaner data and eliminates the time-consuming process of source data verification.
Clinical Ink launched in 2013 and has raised nearly $15 million in capital spread across four rounds of financing.
The filing was submitted on Dec. 28.
